Cellular Biomedicine Group Net Income

As of the most recent data (September 2020), CBMG shows a net income of $-55M. That compares with $-46M in the prior-year period — down 19.6% year over year. That is below the Healthcare sector average of $16B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CBMG's net income is now $-55M (was $-46M) — a 19.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Cellular Biomedicine Group is outperforming or lagging.

The Healthcare sector average net income is about $16B. Cellular Biomedicine Group is at $-55M, which is lower that average. That is roughly 100.3% below the sector mean. Use the comparison chart on this page to see how CBMG stacks up against individual peers as well.

Tracking CBMG's net income over time shows whether Cellular Biomedicine Group is scaling, shrinking, or reshaping that part of the business. The current reading is $-55M That compares with $-46M in the prior-year period — down 19.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net income page, Stockcircle has Cellular Biomedicine Group's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net income (currently $-55M) with ownership activity and broader fundamentals.